1. Product Overview
1.1. Market
Definition
1.2. Scope
of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective
of the Study
2.2. Baseline
Methodology
2.3. Key
Industry Partners
2.4. Major
Association and Secondary Sources
2.5. Forecasting
Methodology
2.6. Data
Triangulation & Validation
2.7. Assumptions
and Limitations
3. Executive Summary
3.1. Overview
of the Market
3.2. Overview
of Key Market Segmentations
3.3. Overview
of Key Market Players
3.4. Overview
of Key Regions/Countries
3.5. Overview
of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Benign Prostate Hyperplasia (BPH) Devices Market
Outlook
5.1. Market
Size & Forecast
5.1.1. By Value
5.2. Market
Share & Forecast
5.2.1. By Drug Treatment
(Alpha Blockers, 5-Alpha Reductase Inhibitors, and Phosphodiesterase-5
Inhibitors)
5.2.2. By Surgical Treatment
(Transurethral resection of the prostate (TURP), Prostatic Urethral Lift (PUL),
Prostatectomy, laser surgery, Transurethral microwave Technique (TUMT),
Transurethral needle ablation of the prostate (TUNA), and others (Rezum
therapy, Urolift therapy, etc)
5.2.3. By End User (hospitals
and clinics, ambulatory surgical Centers, and Others)
5.2.4. By Region (North
America, Europe, Asia Pacific, South America, Middle East & Africa)
5.2.5. By Company (2024)
5.3. Market
Map
6. North America Benign Prostate Hyperplasia (BPH) Devices
Market Outlook
6.1. Market
Size & Forecast
6.1.1. By Value
6.2. Market
Share & Forecast
6.2.1. By Drug Treatment
6.2.2. By Surgical Treatment
6.2.3. By End User
6.2.4. By Country
6.3. By
Region North America: Country Analysis
6.3.1. United States Benign Prostate Hyperplasia (BPH) Devices
Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Treatment
6.3.1.2.2. By Surgical Treatment
6.3.1.2.3. By End User
6.3.2. Canada Benign Prostate Hyperplasia (BPH) Devices Market
Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Treatment
6.3.2.2.2. By Surgical Treatment
6.3.2.2.3. By End User
6.3.3. Mexico Benign Prostate Hyperplasia (BPH) Devices Market
Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Treatment
6.3.3.2.2. By Surgical Treatment
6.3.3.2.3. By End User
7. Europe
Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
7.1. Market Size &
Forecast
7.1.1. By Value
7.2. Market
Share & Forecast
7.2.1. By Drug Treatment
7.2.2. By Surgical Treatment
7.2.3. By End User
7.2.4. By
Country
7.3. Europe:
Country Analysis
7.3.1. France Benign Prostate Hyperplasia (BPH) Treatment Market
Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Treatment
7.3.1.2.2. By Surgical Treatment
7.3.1.2.3. By End User
7.3.2. Germany Benign Prostate Hyperplasia (BPH) Treatment Market
Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Treatment
7.3.2.2.2. By Surgical Treatment
7.3.2.2.3. By End User
7.3.3.United
Kingdom Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Treatment
7.3.3.2.2. By Surgical Treatment
7.3.3.2.3. By End User
7.3.4. Italy Benign Prostate Hyperplasia (BPH) Treatment Market
Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drug Treatment
7.3.4.2.2. By Surgical Treatment
7.3.4.2.3. By End User
7.3.5. Spain Benign Prostate Hyperplasia (BPH) Treatment Market
Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drug Treatment
7.3.5.2.2. By Surgical Treatment
7.3.5.2.3. By End User
8. Asia-Pacific Benign Prostate Hyperplasia (BPH) Treatment
Market Outlook
8.1. Market
Size & Forecast
8.1.1. By Value
8.2. Market
Share & Forecast
8.2.1. By Drug Treatment
8.2.2. By Surgical Treatment
8.2.3. By End User
8.2.4. By
Country
8.3. Asia-Pacific:
Country Analysis
8.3.1. China Benign Prostate Hyperplasia (BPH) Treatment Market
Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Treatment
8.3.1.2.2. By Surgical Treatment
8.3.1.2.3. By End User
8.3.2. Japan Benign Prostate Hyperplasia (BPH) Treatment Market
Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Treatment
8.3.2.2.2. By Surgical Treatment
8.3.2.2.3. By End User
8.3.3. India Benign Prostate Hyperplasia (BPH) Treatment Market
Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Treatment
8.3.3.2.2. By Surgical Treatment
8.3.3.2.3. By End User
8.3.4. South Korea Benign Prostate Hyperplasia (BPH) Treatment
Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Treatment
8.3.4.2.2. By Surgical Treatment
8.3.4.2.3. By End User
8.3.5. Australia Benign Prostate Hyperplasia (BPH) Treatment
Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Treatment
8.3.5.2.2. By Surgical Treatment
8.3.5.2.3. By End User
9. South America Benign Prostate Hyperplasia (BPH) Treatment
Market Outlook
9.1. Market
Size & Forecast
9.1.1. By Value
9.2. Market
Share & Forecast
9.2.1. By Drug Treatment
9.2.2. By Surgical Treatment
9.2.3. By End User
9.2.4. By
Country
9.3. South
America: Country Analysis
9.3.1. Brazil Benign Prostate Hyperplasia (BPH) Treatment Market
Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Treatment
9.3.1.2.2. By Surgical Treatment
9.3.1.2.3. By End User
9.4. Argentina
Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
9.4.1.1. Market Size & Forecast
9.4.1.1.1. By Value
9.4.1.2. Market Share & Forecast
9.4.1.2.1. By Drug Treatment
9.4.1.2.2. By Surgical Treatment
9.4.1.2.3. By End User
9.5. Colombia
Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
9.5.1.1. Market Size & Forecast
9.5.1.1.1. By Value
9.5.1.2. Market Share & Forecast
9.5.1.2.1. By Drug Treatment
9.5.1.2.2. By Surgical Treatment
9.5.1.2.3. By End User
10. Middle East and Africa Benign Prostate Hyperplasia (BPH)
Treatment Market Outlook
10.1. Market Size & Forecast
10.1.1. By
Value
10.2. Market Share & Forecast
10.2.1. By
Drug Treatment
10.2.2. By
Surgical Treatment
10.2.3. By
End User
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. UAE
Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Treatment
10.3.1.2.2. By Surgical Treatment
10.3.1.2.3. By End User
10.3.2. Saudi
Arabia Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Treatment
10.3.2.2.2. By Surgical Treatment
10.3.2.2.3. By End User
10.3.3. South
Africa Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug Treatment
10.3.3.2.2. By Surgical Treatment
10.3.3.2.3. By End User
10.3.4. Turkey
Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Drug Treatment
10.3.4.2.2. By Surgical Treatment
10.3.4.2.3. By End User
10.3.5. Egypt
Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
10.3.5.1. Market Size & Forecast
10.3.5.1.1. By Value
10.3.5.2. Market Share & Forecast
10.3.5.2.1. By Drug Treatment
10.3.5.2.2. By Surgical Treatment
10.3.5.2.3. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
13. Clinical Trial Analysis
13.1. Ongoing Clinical Trials
13.2. Completed Clinical Trials
13.3. Terminated Clinical Trials
13.4. Breakdown of Pipeline, By Development Phase
13.5. Breakdown of Pipeline, By Status
13.6. Breakdown of Pipeline, By Study Type
13.7. Breakdown of Pipeline, By Region
13.8. Clinical Trials Heat Map
14. Competitive Landscape
14.1. Business Overview
14.2. Product Offerings
14.3. Recent Developments
14.4. Financials (In Case of Listed Companies)
14.5. Key Personnel
14.5.1. Boston
Scientific Corporation
14.5.2. Coloplast
Corporation
14.5.3. Teleflex
Incorporated
14.5.4. Olympus
Corporation
14.5.5. Glaxo
Smith Kline PLC
14.5.6. Eli
Lily
14.5.7. Abott
Laboratories
14.5.8. Medifocus
Inc.
14.5.9. Urologix,
LLC
14.5.10. Pfizer
Inc
15. Strategic
Recommendations
16. About Us
and Disclaimer